TM Editors Note: Many of the companies mentioned in this article are penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.

This article tracks the performance of 15 of the 35 biopharmaceutical companies involved in the research and development of psychedelic compounds to treat mental health issues such as obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders in the munKNEE Pure-Play Psychedelic Drug Stocks Index.

Index Inclusion Criteria

The 15 stocks eligible for inclusion in the index are based on the following criteria:

• a market capitalization between US$20M and US$200M (current average Market Cap is US$44M)
• a stock that trades between US$0.20/share and US$2/share (current average Stock Price is US$0.85/share)

Below are the 15 eligible companies in the munKNEE Pure-Play Psychedelic Drug Stocks Index and their performance for the first week of January, 2021. All prices are in USD unless otherwise noted.

1. Champignon (SHRMF) +1.6% to $0.63/share
2. Cybin (CLXPF) +4.7% to $1.57/share
3. Havn (HAVLF) -6.5% to $0.72/share
4. Hollister (HSTRF) +30.0% to $0.26/share
5. Jaguar (JAGX) +393.8% to $4.00/share
   • Jaguar Health's stock price continues to climb (up 1900% since the end of October) as a result of management's announcement of its plan to develop and commercialize crofelemer, a new drug aimed at helping people with inflammatory diarrhea, including those who have recovered from COVID-19 but still experiencing symptoms.
6. Mind Cure (MCURF) +1.8% to $0.58/share
7. Mydecine (MYCOF) -2.9% to $0.34/share
8. Newscope (PHRM) +6.3% to C$0.34/share
9. Numinus (LKYSF) +16.7% to $0.98/share
10. Psyched (DCNPF) +4.5% to $0.23/share
11. Red Light (TRUFF) N/C @ $0.24/share 
12. Revive (RVVTF) N/C @ $0.48/share
13. Seelos (SEEL) -8.9% to $1.44/share
14. Silo Pharma (SILO) -16.7% to $0.35/share
15. Tryp (TRYP) -16.0% to C$0.63/share

The above 15 psychedelic drug stocks increased, on average, by 32.3% during the first week of January, 2021, building on the 58.4% increase in December and 48.7% in November. That being said, were the out-sized gain by Jaguar excluded from the index the increases would have been +46.4% in November, +69.1% in December and -0.8% during the first week of January.

When "big pharma" realizes the potential of psychedelics in treating mental health issues many of the companies identified in this article will be bought out and those that remain should see their stock prices continue to undergo major appreciation. Do your own due diligence and to determine if any of these stocks belong in your portfolio.